CRB-913 was safe and well-tolerated across all doses studied Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participants A placebo-adjusted mean weight loss of ...

Preclinical and Phase 1 study published in Nature Medicine describes clinical and mechanistic validation for OrsoBio's LXR ...

Recent advances in immunology have underscored the pivotal role of the transcription factor RORγt in orchestrating the differentiation of Th17 cells and the consequent production of proinflammatory ...

NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced the Company’s plan to release ...

(RTTNews) - Corbus Pharmaceuticals Holdings Inc. (CRBP) will present results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist, for the treatment of obesity during a webcast scheduled ...

CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabant SAD/MAD Phase 1 trial scheduled ...

When eating, the body converts extra calories, especially from carbs, sugar, fats, and alcohol, into triglycerides.